Alyx B Porter, Heshan Liu, Sadhna Kohli, Jane L Cerhan, Jeff Sloan, Ryan P McMurray, Jennifer Le-Rademacher, Charles L Loprinzi, John L Villano, Sani H Kizilbash, Minesh P Mehta, Kurt A Jaeckle, Paul D Brown
Importance: Nearly 96% of patients with high-grade glioma (HGG) report moderate-to-severe fatigue. Armodafinil is a psychostimulant that might help cancer-related fatigue in patients with HGG. Objective: To determine whether armodafinil reduces fatigue in patients with HGG and moderate-to-severe fatigue. Design, Setting, and Participants: In this randomized multicenter, phase 3, double-blinded, placebo-controlled clinical trial, adults with HGG and moderate-to-severe fatigue who were clinically stable at least 4 weeks after completing radiation therapy were randomized to receive armodafinil daily (150 mg or 250 mg) or placebo over 8 weeks...
December 9, 2021: JAMA Oncology